AIMS: Existing evidence suggests that amyloid-β precursor protein (APP) causes endothelial dysfunction and contributes to pathogenesis of atherosclerosis. In the present study, experiments were designed to: (1) determine the mechanisms underlying endothelial dysfunction and (2) define the effects of peroxisome proliferator-activated receptor delta (PPARδ) ligand on endothelial function in transgenic Tg2576 mice overexpressing mutated human APP. METHODS AND RESULTS: Confocal microscopy and western blot analyses of wild-type mice aortas provided evidence that APP protein is mainly present in endothelial cells. Overexpression of APP significantly impaired endothelium-dependent relaxations to acetylcholine and phosphorylation of endothelial nitric oxide synthase at Ser(1177) in aortas. HPLC analysis revealed that tetrahydrobiopterin (BH(4)) levels were reduced in Tg2576 mice aortas. This was caused by increased oxidation of BH(4) and reduced expression and activity of GTP-cyclohydrolase I. Furthermore, gp91phox protein expression and superoxide anion production were increased in aortas of Tg2576 mice. This augmented superoxide formation was completely prevented by the NADPH oxidase inhibitor VAS2870. Expression of copper-/zinc-superoxide dismutase (Cu/ZnSOD) and extracellular SOD was downregulated. Treatment with PPARδ ligand GW501516 (2 mg/kg/day) for 14 days significantly increased BH(4) bioavailability and improved endothelium-dependent relaxations in Tg2576 mice aortas. GW501516 also normalized protein expression of gp91(phox) and SODs, thereby reducing production of superoxide anion in the aortas. CONCLUSION: Our results suggest that in APP transgenic mice loss of nitric oxide and increased oxidative stress are the major causes of endothelial dysfunction. The vascular protective effects of GW501516 in Tg2576 mice appear to be critically dependent on prevention of superoxide anion production.
AIMS: Existing evidence suggests that amyloid-β precursor protein (APP) causes endothelial dysfunction and contributes to pathogenesis of atherosclerosis. In the present study, experiments were designed to: (1) determine the mechanisms underlying endothelial dysfunction and (2) define the effects of peroxisome proliferator-activated receptor delta (PPARδ) ligand on endothelial function in transgenic Tg2576mice overexpressing mutated human APP. METHODS AND RESULTS: Confocal microscopy and western blot analyses of wild-type mice aortas provided evidence that APP protein is mainly present in endothelial cells. Overexpression of APP significantly impaired endothelium-dependent relaxations to acetylcholine and phosphorylation of endothelial nitric oxide synthase at Ser(1177) in aortas. HPLC analysis revealed that tetrahydrobiopterin (BH(4)) levels were reduced in Tg2576mice aortas. This was caused by increased oxidation of BH(4) and reduced expression and activity of GTP-cyclohydrolase I. Furthermore, gp91phox protein expression and superoxide anion production were increased in aortas of Tg2576mice. This augmented superoxide formation was completely prevented by the NADPH oxidase inhibitor VAS2870. Expression of copper-/zinc-superoxide dismutase (Cu/ZnSOD) and extracellular SOD was downregulated. Treatment with PPARδ ligand GW501516 (2 mg/kg/day) for 14 days significantly increased BH(4) bioavailability and improved endothelium-dependent relaxations in Tg2576mice aortas. GW501516 also normalized protein expression of gp91(phox) and SODs, thereby reducing production of superoxide anion in the aortas. CONCLUSION: Our results suggest that in APP transgenic mice loss of nitric oxide and increased oxidative stress are the major causes of endothelial dysfunction. The vascular protective effects of GW501516 in Tg2576mice appear to be critically dependent on prevention of superoxide anion production.
Authors: W R Oliver; J L Shenk; M R Snaith; C S Russell; K D Plunket; N L Bodkin; M C Lewis; D A Winegar; M L Sznaidman; M H Lambert; H E Xu; D D Sternbach; S A Kliewer; B C Hansen; T M Willson Journal: Proc Natl Acad Sci U S A Date: 2001-04-17 Impact factor: 11.205
Authors: C Iadecola; F Zhang; K Niwa; C Eckman; S K Turner; E Fischer; S Younkin; D R Borchelt; K K Hsiao; G A Carlson Journal: Nat Neurosci Date: 1999-02 Impact factor: 24.884
Authors: L V d'Uscio; T A Baker; C B Mantilla; L Smith; D Weiler; G C Sieck; Z S Katusic Journal: Arterioscler Thromb Vasc Biol Date: 2001-06 Impact factor: 8.311
Authors: Guido R Y De Meyer; Dieter M M De Cleen; Susan Cooper; Michiel W M Knaapen; Dominique M Jans; Wim Martinet; Arnold G Herman; Hidde Bult; Mark M Kockx Journal: Circ Res Date: 2002-06-14 Impact factor: 17.367
Authors: Marcos L Sznaidman; Curt D Haffner; Patrick R Maloney; Adam Fivush; Esther Chao; Donna Goreham; Michael L Sierra; Christelle LeGrumelec; H Eric Xu; Valerie G Montana; Millard H Lambert; Timothy M Willson; William R Oliver; Daniel D Sternbach Journal: Bioorg Med Chem Lett Date: 2003-05-05 Impact factor: 2.940
Authors: Laibaik Park; Joan Zhou; Ping Zhou; Rose Pistick; Sleiman El Jamal; Linda Younkin; Joseph Pierce; Andrea Arreguin; Josef Anrather; Steven G Younkin; George A Carlson; Bruce S McEwen; Costantino Iadecola Journal: Proc Natl Acad Sci U S A Date: 2013-02-04 Impact factor: 11.205